Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
Lists
Only you see this
Abstract
Within patients treated for EGFRm metastatic NSCLC before 2015, absence of brain metastasis and nonsmoking status were predictive of 5-year survival. Our findings help to define a subset of patients with EGFRm NSCLC with excellent survival outcomes who may not require intensification of initial therapy.
BibTeX
@inproceedings{tompkins2024characteristics,
author = {William Tompkins and Connor B. Grady and Wei‐Ting Hwang and Krishna Chandrasekhara and Caroline E. McCoach and Fangdi Sun and Geoffrey Liu and Devalben Patel and Jorge J. Nieva and Amanda Herrmann and Kristen A. Marrone and Vincent K. Lam and Vamsi Velcheti and Stephen V. Liu and Gabriela Liliana Bravo Montenegro and Tejas Patil and Jared Weiss and Kelsey Leigh Miller and William Schwartzman and Jonathan E. Dowell and Khvaramze Shaverdashvili and Liza C. Villaruz and Amanda Cass and Wade T. Iams and Dara L. Aisner and Charu Aggarwal and D. Ross Camidge and Melina E. Marmarelis and Lova Sun},
title = {{Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC}},
booktitle = {JTO},
year = {2024},
doi = {10.1016/j.jtocrr.2024.100669},
}Loading related content...